Paul Copeland, DO
Child & Adolescent Psychiatry · West Sacramento, CANPI 1477667152
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 33.4% of the total.
Across 56 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$301
- Takeda Pharmaceuticals U.S.A., Inc.$162
- Adlon Therapeutics L.p.$96
- Tris Pharma Inc$84
- Supernus Pharmaceuticals, Inc.$68
- Lundbeck LLC$42
- plus $148 from 5 others
What the payments were for
- Food & beverage$902100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$902 in reported general payments places this provider in the 75th percentile of 434 child & adolescent psychiatry providers in California.
See all child & adolescent psychiatry providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 26 | $93,698 |
| Lurasidone Hcl | 130 | $37,071 |
| Quetiapine Fumarate | 570 | $14,714 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 46 | $14,317 |
| Aripiprazole | 240 | $13,928 |
| Olanzapine | 721 | $12,656 |
| Chlorpromazine Hcl | 26 | $10,529 |
| Clozapine | 129 | $10,359 |
| Paliperidone ErPaliperidone | 39 | $7,801 |
| Olanzapine OdtOlanzapine | 24 | $6,568 |
| Divalproex Sodium | 151 | $6,203 |
| Risperidone OdtRisperidone | 23 | $5,581 |
| Risperidone | 362 | $4,655 |
| Ziprasidone Hcl | 81 | $4,453 |
| Haloperidol | 94 | $4,026 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in West Sacramento
- Kevin CoxOjai$2.9M
- Sukhjit BrarFresno$283K
- Manpreet SinghSacramento$104K
- Ihab SolimanCorona del Mar$93K
- Syed NaqviLos Angeles$69K
- Ellen HeynemanSan Diego$62K
- Mark McDonaldLos Angeles$31K
- James HartmanDanville$21K
- Mohsin KhaliqueSan Ramon$20K
- Mansoor ZuberiWalnut Creek$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.